)
Visual
test
Senti Biosciences
Senti Biosciences (SNTI) investor relations material
Senti Biosciences Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary27 Mar, 2026
Executive summary
Advanced lead program SENTI-202 with positive preliminary Phase 1 data in relapsed/refractory AML, showing encouraging response rates and favorable safety profile.
Received RMAT designation from FDA for SENTI-202, supporting regulatory momentum.
Continued progress in pipeline and synthetic biology platform, focusing on Gene Circuit-engineered cell therapies.
Maintained disciplined capital management to support key milestones.
Financial highlights
Cash and cash equivalents stood at $16.4 million as of December 31, 2025, down from $48.3 million at year-end 2024.
Research and development expenses totaled $37.6 million for 2025, up from $34.4 million in 2024.
General and administrative expenses were $26.2 million for 2025, slightly down from $26.4 million in 2024.
Net loss for 2025 was $61.4 million, or $2.73 per share, compared to $52.8 million, or $12.03 per share, in 2024.
Q4 2025 net loss was $14.5 million, or $0.53 per share.
Outlook and guidance
Focus remains on advancing key programs toward critical development milestones and expanding Gene Circuit platform capabilities.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Senti Biosciences
- SENTI-202 achieved 42% CR/CRh in AML with strong safety and rapid recovery, advancing to pivotal trials.SNTI
Leerink Global Healthcare Conference 20269 Mar 2026 - SENTI-202 delivers deep, durable AML responses with broad eligibility and strong clinical momentum.SNTITD Cowen 46th Annual Health Care Conference3 Mar 2026
- SENTI-202 and SENTI-301A advance clinical cell therapies with Logic Gate technology for cancer.SNTIH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Multi-target cell therapies advance in AML and liver cancer, with key data readouts ahead.SNTIChardan's 8th Annual Genetic Medicines Conference20 Jan 2026
- SENTI-202 demonstrates durable, selective efficacy in AML, with expansion into solid tumors planned.SNTIH.C. Wainwright 27th Annual Global Investment Conference31 Dec 2025
- Biotech seeks $300M via shelf, faces going concern risk and dilution; Leerink Partners leads ATM.SNTIRegistration Filing16 Dec 2025
- Highly dilutive PIPE resale registration funds R&D amid financial uncertainty and investor-led governance.SNTIRegistration Filing16 Dec 2025
- 50% ORR and 42% CR/CRh with deep, durable, MRD-negative remissions and high safety.SNTIStudy Update9 Dec 2025
- Stockholders to vote on major stock issuance, equity plan expansion, and meeting adjournment.SNTIProxy Filing2 Dec 2025
Next Senti Biosciences earnings date
Q1 20265 May, 2026
Senti Biosciences
Next Senti Biosciences earnings date
Q1 20265 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage